NCT03909100已完成不适用
International CoolSculpting: Prospective, Multi-Country, Study to Evaluate Patient Satisfaction for Non-Invasive Fat Reduction in Abdomen and/or Flanks (iCOOL)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 120
- 试验地点
- 7
- 主要终点
- Percentage of Participants Who Reported "Satisfied" or "Very Satisfied" on Cryolipolysis Satisfaction Questionnaire (CSQ) Item #1 Overall
研究概览
简要总结
This study aims to generate data that conveys participant's experiences such as their overall satisfaction with the CoolSculpting® treatment for their belly and love handles. By doing this, the study will provide insights for doctors to better inform participants about the expected outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant has clearly visible fat in the flanks and/or abdomen, which in the investigator's opinion, may benefit from the treatment.
- •Participant has not had weight change fluctuations exceeding 4.5 kg (or 5% of body weight) in the preceding month.
- •Participant has a body mass index (BMI) of 18.5 to
- •A BMI is defined as weight in kilograms divided by height in meters squared (kg/m2).
- •Participant agrees to maintain weight (ie, within 5% of body weight) by not making any changes in diet or exercise routine during the course of the study.
- •Participant agrees to have photographs taken of the treatment area(s) during the scheduled time periods.
排除标准
- •Participant has had liposuction, or another surgical procedure(s) or mesotherapy in area of intended treatment.
- •Participant has had a non-invasive fat reduction and/or body contouring procedure in the area(s) of intended treatment within the past 12 months.
- •Participant needs to administer, or has a known history of subcutaneous injections into the area(s) of intended treatment (eg, cortisone, heparin, insulin) within the past 6 months.
- •Participant is pregnant or intending to become pregnant.
- •Participant is lactating or has been lactating in the past 6-9 months.
- •Participant is unable or unwilling to comply with study requirements.
- •Participant is currently enrolled in a clinical study of any unapproved investigational device, investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
- •Participant has an active implanted device such as a pacemaker, defibrillator, or drug delivery system or any other metal containing implant.
- •Participant with known history of cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.
- •Participant with known sensitivity to cold or has any condition with a known response to cold exposure that limits blood flow to the skin such as cold urticaria or Raynaud's disease, or Chilblains (pernio).
- •Participant with known sensitivity or allergy to fructose, glycerin, isopropyl alcohol, or propylene glycol.
- •Participant with impaired peripheral circulation in the area to be treated
- •Participant with neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy.
- •Participant with impaired skin sensation.
- •Participant with open or infected wounds.
- •Participant with bleeding disorders, or concomitant use of blood thinners, or is taking any medication that in the investigator's opinion may increase the participant's risk of bruising.
- •Participant with recent surgery or scar tissue in the area to be treated.
- •Participant has history of hernia in or adjacent to the treatment area(s) site.
- •Participant with skin conditions such as eczema, dermatitis, or rashes in the area to be treated.
- •Participant has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
- •Participant is taking or has taken diet pills or supplements within the past 6 months.
- •Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the participant's response or the integrity of the data or would pose an unacceptable risk to the participant.
- •Participant diagnosed with fibrosis.
研究组 & 干预措施
CoolSculpting® System
Experimental
Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
干预措施: CoolSculpting® System (Device)
结局指标
主要结局
Percentage of Participants Who Reported "Satisfied" or "Very Satisfied" on Cryolipolysis Satisfaction Questionnaire (CSQ) Item #1 Overall
时间窗: 12 weeks after the final treatment session (measured at Week 12 for participants who received 1 treatment session or Week 20 for 2 treatment sessions)
The CSQ is a 4-item Patient-reported Outcome (PRO) instrument that measures the participant's satisfaction with CoolSculpting® treatment of the flank, abdomen or both. Participants rated their satisfaction by answering CSQ Item 1="Rate your overall satisfaction with the fat reduction procedure on the treated area" using the following scale: Very satisfied, Satisfied, Neither satisfied nor dissatisfied, Dissatisfied or Very dissatisfied.
次要结局
- Percentage of Participants by Body Mass Index (BMI) Categories Who Reported "Satisfied" or "Very Satisfied" on CSQ Item #1(12 weeks after the final treatment session (measured at Week 12 for participants who received 1 treatment session or Week 20 for 2 treatment sessions))
- Change From Baseline in Volume of Fat as Measured by 3 Dimensional (3D) Photography(Baseline to 8 Weeks post-Treatment 1 and 12 Weeks post-Final Treatment 2)
- Percentage of Participants With Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs)(First treatment to Follow-up/Exit Visit (Week 12 +/- 14 days for those participants who received 1 treatment and Week 20 +/- 14 days for those participants who received 2 treatments))
- Percentage of Participants Who Reported "Satisfied" or "Very Satisfied" on CSQ Item #1 in Treated Area(s)(12 weeks after the final treatment session (measured at Week 12 for participants who received 1 treatment session or Week 20 for 2 treatment sessions))
- Percentage of Participants Who Received 1 or 2 Treatments Who Reported "Satisfied" or "Very Satisfied" on CSQ Item #1 by Number of Treatment Cycles(12 weeks after the final treatment session (measured at Week 12 for participants who received 1 treatment session or Week 20 for 2 treatment sessions))
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(First treatment to Follow-up/Exit Visit (Week 12 +/- 14 days for those participants who received 1 treatment and Week 20 +/- 14 days for those participants who received 2 treatments))
研究者
研究点 (7)
Loading locations...
相似试验
已完成
4 期
CoolSculpting® Elite for Non-Invasive Fat ReductionNon-invasive Fat ReductionNCT04897867Allergan110
已完成
不适用
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in AdultsPlaque PsoriasisNCT05811234Almirall, S.A.291
已完成
4 期
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or OsteopeniaPostmenopausal OsteoporosisNCT02604836Hoffmann-La Roche1,711
已完成
4 期
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar LinesGlabellar LinesWrinklesNCT02718118Galderma R&D60
进行中（未招募）
不适用
MiDura-Study (Neuro-Patch in Duraplasty)Tumor, BrainDural FistulaDuraplastyHydrocephalusVascular MalformationChiari MalformationCraniotomyMeningiomaSpinal SurgeryTethered CordNCT04189172Aesculap AG328